Triclabendazole

  • TRADE NAME: Egaten (Novartis)
  • INDICATIONS: Indicated for the treatment of fascioliasis in patients 6 years of age and older.
  • SYNONYM: Egaten
  • CLASS: Anthelmintic
  • HALF-LIFE: 8 hours

FDA APPROVAL DATE: 02/13/2019

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
There are no available data on use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.

QT Prolongation: May prolong QT interval. Monitor ECG in patients with a history of QT prolongation or who are taking medications which prolong the QT interval.

Our database has 22 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
NEUROMUSCULAR/SKELETAL
RESPIRATORY


Page last updated 03/18/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric